key: cord-0841527-s84f7vi0
authors: Lino, A.; Cardoso, M. A.; Martins‐Lopes, P.; Gonçalves, H. M. R.
title: Omicron – The new SARS‐CoV‐2 challenge?
date: 2022-04-21
journal: Rev Med Virol
DOI: 10.1002/rmv.2358
sha: e51e5215ab2245bc521391114c3baccdaca63ad8
doc_id: 841527
cord_uid: s84f7vi0

SARS‐CoV‐2 virus has infected nearly 300 M people worldwide and has been associated with over 6 M deaths by March 2022. Since the virus emergence in December 2019 in Wuhan, several new mutations have been described. The World Health Organization has developed a working name for these emerging variants according to their impact on the worldwide population. In this context a high alert has been paid to variants of concern (VOC) due to their high infectiousness and transmissibility patterns. The most recent VOC, Omicron (B.1.1.529), has become dominant in the shortest time ever and has placed Europe under an overwhelming and unprecedented number of new cases. This variant has numerous mutations in regions that are associated with higher transmissibility, stronger viral binding, affinity and antibody escape. Moreover, the mutations and deletions present in the spike protein suggest that the SARS‐CoV‐2 specific attachment inhibitors may not be the best option for Omicron therapy. Omicron is the dominant variant circulating worldwide and, at the end of February 2022, it was responsible for nearly all sequences reported to GISAID. Omicron is made up of several sublineages, where the most common are BA.1 and BA.2 (or Nextstrain clade 21K and 21L, respectively). At a global level, it is possible to say that the proportion of BA.2 has been increasing relative to BA.1 and in some countries it has been replacing it at high rates. In order to better assess the Omicron effectiveness on antibody escape, spread and infectious ability it is of the highest relevance to maintain a worldwide tight surveillance. Even though this variant has been associated with a lower death rate, it is important to highlight that the number of people becoming infected is concerning and that further unpredictable mutations may emerge as the number of infected people rises.

The first sequenced SARS-CoV-2 genome was made public on 5 th of January 2020, and since then, more than 3 million genome sequences have been shared on online platforms worldwide, allowing a comparative genomic analysis. 1 This strategy of sequencing a high number of genomes has also enabled the scientific community to follow and keep track of the virus evolution, which was fundamental for the development of more adequate detection methods and treatments, alongside with the detection of emerging new variants. The scientific knowledge acquired so far has allowed the establishment of phylogenetic relationships of SARS-CoV-2 with other known virus. Indeed, the first sequenced genomes revealed a similarity of 96% with a bat coronavirus (RaTG13), which indicates that bats were probably reservoir hosts or even the origin of this virus. 2, 3 However, there is not a consensus among the scientific community regarding whether bats were the direct source or if they were an intermediate host. 4 A fact that is commonly accepted is that the binding receptors are fundamental to better understand the disease evolution upon infection. In MERS-CoV, for example, it was found that preexisting pulmonary disease could increase the dipeptidylpeptidase 4 (DPP4) abundance and, thus, predispose individuals to morbidity and mortality. DPP4 preferential spatial localization in alveolar regions may explain why MERS-CoV is characterised has being a lower respiratory tract disease. 5 On the other hand, SARS-CoV-2 and SARS-CoV use the S protein to bind to angiotensin-converting enzyme 2 (ACE2), 6 a protein that can be found on the surface of many cell types ( Figure 1 ).

Another interesting feature of SARS-CoV-2 is the presence of a nonstructural protein (nsp14) that lowers the known high mutation rate of RNA virus due to its proofreading ability. 7 Despite this proofreading ability, the high recombination rates and, consequently genetic variability of RNA viruses, facilitates the emergence of new mutations and viral variants, thus reinforcing the need for a constant genetic monitoring of SARS-CoV-2. 8 Analysing the genome-wide patterns on mutations distribution and accumulation, there is a clear lower incidence in genes encoding nsps when compared to genes encoding structural and accessory proteins. This is a really interesting feature of this virus and is probably due to the fact that nsps play a key role in the viral life cycle. Indeed, they are responsible for the formation of the replication and transcription complex (RTC), which enables virus replication, and have a fundamental role in the host's immune response evasion on the initial stage of infection. In contrast, some structural and accessory proteins seem to be more prone to mutations. For example, ORF6 and ORF8 are regions with high mutational rates, most likely due to their involvement in immune response escape upon cell entry and initial infection stage, which may benefit from some of these mutations. 9 Moreover, the S gene seems to be not only a mutational hotspot, but it also has a dN/dS ratio above 1, which is indicative of positive selection. 10 Considering the role of the S protein in the viral life cycle (responsible for the virus binding to the host cell receptor ACE2 and the initiation of the infection process) the existence of a mutation hotspot in this zone may indicate a viral molecular strategy to increase SARS-CoV-2 virulence and transmissibility. 11, 12 The follow-up of this and other mutations has led to the identification of new SARS-CoV-2 variants.

The high worldwide surveillance on SARS-CoV-2 genetic alterations has allowed the identification of new variants in a timely manner. 13 The majority of the mutations identified are synonymous mutations, that is, nucleotide substitutions that don't alter the encoded amino acid. This type of mutation won't have an effect in viral characteristics, for example, transmission and virulence, but can compromise some COVID-19 diagnosis molecular methods. The majority of the SARS-CoV-2 genome appears to sustain this type of mutations, hence being under purifying or negative selection. On the other side, non-F I G U R E 1 Schematic representation of SARS-CoV-2 virus on the right and an amplification of the Spike protein with its representative domains on the left synonymous mutations will probably change SARS-CoV-2 phenotype.

The consequences can vary from imperceptible, on the pathogenic level, to major repercussions on virulence, transmissibility, and general disease prognosis. The first clinically significant non-synonymous mutation detected was an A to G transition at position 23,403 in the S gene. 14 This amino acid change, also known as the D614 G variant, is suspected to have emerged in January 2020 and 5 months later it was the dominant variant in circulation worldwide, replacing the original variant found in Wuhan. 15 This rapid variant prevalence has been explained by both higher infection and transmission rates. 15, 16 Since then, several other variants with clinical consequences have emerged, leading to the need to categorise them into different groups, according to the risk they pose to public health. 17, 18 In this sense the World Health Organization ( two additional amino acids monitored: 417N and 484K. Lastly, Omicron was reported in many countries in November 2021. Even though most papers report its appearance in South Africa, according to the WHO 20 it has not yet been assigned to a country. This variant was classified as VUM upon its discovery, but within 4 days, the WHO classification was changed to VOC. The additional amino acid change monitored is R346 K. 19, 20 It is believed that this variant is a case of inter-species evolutionary trajectory, where a mouse was infected with SARS-CoV-2 and upon mutation jumped back to humans and started the high infection rates that we are currently dealing with. 21 Recently, France has reported 12 new cases of a new variant, IHU, that seem to be associated to a patient that returned from Cameroon. 22 From these, 14 are located in the spike protein, including the mutations recently observed in Omicron: N501Y and E484 K, that are associated with antibodies escape. 22 Moreover, the P681H, which was also found in Omicron, has also raised concern since it is located in the spike cleavage site of S1-S2 subunits. 23 On 7 January, virologist Leondios Kostrikis announced that his research group at the University of Cyprus in Nicosia had identified several SARS-CoV-2 genomes that featured elements of both the Delta and Omicron variants, "Deltacron". 24 However, it was assumed to be a contamination or otherwise an experimental error, since the scientific community did not confirmed other cases.

Recently, WHO has confirmed cases in Denmark, the Netherlands, France and United Kingdom. 25 WHO is still waiting for new data that can further clarify this variant potential threat, hence it has still not been classified as a VOC. Nonetheless if we consider that this variant is the fusion between the deadliest VOC and the most transmissible one, with high vaccine-mediated and previous infection immunity, it seems safe to say that the pandemic is far from being over.

The different VOCs have distinct characteristics, nonetheless there seems to be an increasing trend in terms of infectiousness rate. The Delta variant managed to invade 163 countries in an approximately 9 months's period upon being discovered. According to the evidence so far 26 the Delta variant is 40%-60% more transmissible than Alpha.

Moreover, according to the available data, the Delta variant presented a two-fold increased risk of hospitalisation. [27] [28] [29] This led to a high increase, not only on the infected people, but also in hospitalizations and deaths worldwide. On the other hand, Omicron, which was discovered on the 11 th of November 2021, was classified as VOC 15 days later, due to its high number of mutations that could have an impact on the transmissibility and the severity of the disease. Omicron did not fail down on the expectations. Indeed, travel-related occurrences were documented in Belgium, Hong Kong and Israel, 15 days after the variant was initially reported. Globally, all countries have reported Omicron-related cases and it has been declared dominant in several European countries in December 2021, only one month upon discovery 19,26 even in communities with strict measures like the ones reported by South Korea. 30 Kandeel et al. 31 compared the genetic similarities between the VOCs and found that the Omicron had the greatest number of gaps during genome alignment with other SARS-CoV-2 variants. Moreover, according to these authors upon sequence alignment and gaps analysis, they concluded that the Alpha variant was the one that most resembles Omicron. This may be an indication that the Omicron variant was on circulation for some time before it was discovered. 31 Additionally, the authors built a phylogenetic tree with the collected data and concluded that Omicron is phylogenetically distant from other variants, thus producing a monophyletic clade. 31, 32 Omicron has more than 50 mutations overall, and of these, 26 are unique, further building upon the 10 concerning and unique mutations previously observed in Delta ( Figure 3 ) and six from Beta. 33 This fact further supports the theory that the environment may play a unique role for viral adaptation. 33 The overall Omicron incidence by age -especially in children 34region and ethnicity differs markedly from Delta. 35 

Spike glycoprotein is responsible for the virus interaction with ACE2 and, consequently, by the viral internalisation on host cells 41 ( Figure 2 ). As such, to avoid virus attachment, most of the therapeutics and vaccines approved for emergency use have been developed to specifically act and inhibit the ACE2-spike interactions. 42 Thus, understanding the mutations, their possible role and location, is crucial for the design of effective target-specific therapeutics and preventive strategies. 43 Omicron has at least 30 amino acid substitutions in the spike protein, three deletions and an insertion ( Figure 3 ). It is noteworthy to highlight that 15 of these mutations are on the receptor-binding domains (RBD) that are responsible for the spike-ACE2 binding. 44 In order to better assess the effect that these mutations have on the spike binding affinity, Kumar co-workers, 41 conducted a study to determine the highest theoretical docking score between the spike protein and ACE2. In this study a comparison between Omicron, the original Wuhan and Delta variants was established. They concluded that Omicron has the highest affinity towards ACE2 when compared to the other reported variants. 41 Indeed, the Omicron variant is the most divergent so far, which can be seen, for example, in terms of transmissibility. This raises concerns on the vaccine efficiency and risk of reinfection. This apprehension is mainly due to the high mutation rate on the S gene, particularly since many of these mutations are in the receptor binding and the N-terminal domains, that play fundamental roles in ACE2 binding and antibody recognition 45, 46 (Figure 2) . Omicron also has a particular cluster of mutations at the S1-S2 furin cleavage site (H655Y, N679 K, P681H; Figure 3 ) that can be responsible for immune-escape and high transmissibility. 47, 48 It is believed that its transmissibility surpasses the Delta variant, considered the most transmissible up until now. Additionally, there are also 3 amino acid deletions in the ORF1a gene that seem to be related with higher immune evasion. 49, 50 Among the many Omicron mutations, it is also important to highlight the relevance of the mutation E484 in the spike protein. It has been previously demonstrated that this mutation may be critical in avoiding vaccination immunity. 41 This mutation is also present in the Beta and Gamma VOCs, as well as, in the Mu VOI and was found to have a key role in resistance to neutralising antibodies generated by prior infection 51 (Figure 2 ).

It is important to highlight that the effect of Omicron mutations must be seen as a whole. 43 N501Y mutation is responsible for improving the ACE2 receptor binding, which is associated with high transmission rate; however, additional Omicron spike protein modifications may also alter the affinity towards ACE2 receptor. 52 The H655Y mutation is adjacent to the furin cleavage point (Figure 3 ), thus it could speed up spike cleavage and assist transmission.

Furthermore, it can also be responsible for the virus resistance towards monoclonal antibody therapy. 53 Moreover, N679 K mutation is also close to the furin cleavage site and contributes to its polybasic character, which may enhance spike cleavage and help transmission. 43 Overall, there are 15 mutations in the Omicron RBD ( Figure 2 to Omicron, an increase in the theoretical pI was observed, changing from acidic to alkaline (from 6.24 to 7.14, for the Wuhan to Omicron variants, respectively). 26 It is also interesting to notice that despite the fact that Omicron has less 3 amino acids than the Wuhan variant, its molecular weight is higher than Wuhan and Delta variants, as well as its pI. Moreover, when compared to the Delta variant, Omicron has an increase in the following amino acids: arginine (Arg), lysine (Lys), aspartic acid (Asp), and glutamic acid (Glu). These amino acids are responsible for salt bridge formation, thus increasing the stability of the protein, particularly because these amino acids are charged residues that are in an exposed section of the protein. Additionally, Omicron spike core is composed by a high content of non-polar amino acids, which is an advantage feature, since the core is inaccessible to the solvent hence it won't pose as a solubility problem and at the same time it allows rising the protein pI. 54

Considering the mutation rate and all the mutations that have arisen in the SARS-CoV-2 genome, it is important to evaluate the effectiveness of the diagnostic tools available. Indeed, depending on the mutations and differences in infection levels, these may compromise some diagnostic tools if they are not constantly being monitored and updated. Currently there are numerous diagnostic tools available. In Europe alone, there are more than 364 tests approved and available for commercialisation. 55, 56 The difference in test performance regarding specificity and sensitivity, the equipment required, the cost and the information that each result provides are all variables that need to be taken into consideration when choosing the best option. Each test has a more or less specific window of time in which its results have higher accuracy, and sometimes, the test choice simply isn't the most adequate for a given situation, leading to false results. Symptom's presentation, time of infection, type and quality of the sample, are some of the variables that can greatly influence test results and their efficacy. The most accurate test so far is the RT-PCR; however, as in all tests, the targeted genomic region needs to be carefully chosen, more when the virus undergoes such a high number of mutations, which can compromise detection efficiency. It is necessary to highlight that the identification of Omicron in South Africa was possible due to the S-gene target failure approach. 43 Thus, and based on the known changes in the virus genome, the rapid antigen detection tests need urgent re-evaluation for their validity in the detection of Omicron cases.

The vaccine-induced immunity mostly targets the spike protein in an attempt to neutralise the interaction between the protein and ACE2.

In each variant, the spike protein has suffered several mutations; however the 15 RBD mutations pose a great concern. 26, 43, 55 The neutralising capacity of our current interventions, namely vaccines and convalescent plasma, need to be addressed through in vitro assays and in vivo studies 57 ; however this will take some time to accomplish. 58 As previously explained, some of the spike mutations are on immune-dominant regions that are thought to be extremely relevant in the antibody-mediated host defence. 33 Casiriviman and Imdevimad. 36 Additionally, this Omicron lineage was also found 35% more resistant to Sotrovimab, 36 another therapeutic antibody that has been proven useful, in the last VOCs, for decreasing the disease progression risk in high-risk patients with mild-to-moderate COVID-19. 65 Even though this new VOC has been associated with a lower mortality and severity rates, this fact is not synonymous of benign.

On the contrary, there is still much uncover on the effects of long COVID and the long-term effects of severe and mild symptomatic infections. Indeed, a recent study with 785 participants it has been demonstrated that even in mild case infection it is possible to develop brain-related abnormalities due to COVID-19 infection. 78 This study proved that this viral infection can effectively lead to: (i) reduction in the grey matter thickness and tissue-contrast in both orbitofrontal cortex and parahippocampal gyrus; (ii) alteration in tissues markers in regions functionally connected to the primary olfactory cortex, and (iii) reduction in global brain size. Additionally the study participants also revealed an average larger cognitive decline when comparing the scan results obtained upon diagnostic and 141 days later. Moreover no differences were observed between patients that had been hospitalised and those who had mild symptoms that did not require hospitalisation. 78 This reinforces the fact that these brain abnormalities can occur even in mild COVID-19 symptoms cases. This study is possibly a hallmark for proving in vivo degenerative spread of diseases via olfactory pathways, neuroinflammatory events or even the loss of sensory input due to anosmia. It remains unknown whether these effects are reversible or not. 

Coexistence of multiple coronaviruses in several bat colonies in an abandoned mineshaft

A pneumonia outbreak associated with a new coronavirus of probable bat origin

On the origin and evolution of SARS-CoV-2

Dipeptidyl peptidase 4 distribution in the human respiratory tract implications for the Middle East respiratory syndrome

The renin-angiotensin system: a key role in SARS-CoV-2-induced COVID-19

The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins. bioRxiv. 2020:1-22. Published online

Computational inference of selection underlying the evolution of the novel coronavirus, severe acute respiratory syndrome coronavirus 2

Novel SARS-CoV-2 variants: the pandemics within the pandemic

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Early genomic, epidemiological, and clinical description of the SARS-CoV-2 omicron variant in Mexico city

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

The variants question: what is the problem

Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

WHO. Tracking SARS-CoV-2 variants. WHO; 2021. Accessed

SARS-CoV-2 variant classifications and definitions. Cdc. Published online 2021:1-12. Accessed

Evidence for a mouse origin of the SARS-CoV-2 Omicron variant

Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein. medRxiv. 2021

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

Deltacron: the story of the variant that wasn't

WHO. Tracking SARS-CoV-2 variants

Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Hospitalisation associated with SARS-CoV-2 delta variant in Denmark

Predicted COVID-19 positive cases, hospitalisations, and deaths associated with the Delta variant of concern

Estimation of serial interval and reproduction number to quantify the transmissibility of SARS-CoV-2 omicron variant in South Korea

Omicron variant genome evolution and phylogenetics

Selecting models of nucleotide substitution: an application to human immunodeficiency virus 1 (HIV-1)

The omicron variant of SARS-CoV-2: understanding the known and living with unknowns

Features of COVID-19 in children during the omicron wave compared with previous waves in madrid, Spain

Report 49: growth, population distribution and immune escape of Omicron in England

Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant

Virological characteristics of SARS-CoV-2 BA.2 variant. bioRxiv. 2022

Editorial: revised world health organization (WHO) terminology for variants of concern and variants of interest of SARS-CoV-2

Two years of COVID: three things we got wrong, and three things to look out for -ABC News

Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. medRxiv. 2022

Structural and molecular perspectives of SARS-CoV-2

Therapeutic approaches for SARS-CoV-2 infection

Characterization of the novel SARS-CoV-2 omicron (B.1.1.529) variant of concern and its global perspective

Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions

Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution

Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity

Covid-19: the E484K mutation and the risks it poses

Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy

A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations

Rapid and accurate identification of SARS-CoV-2 variants containing E484 mutation

The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Protection of Omicron sublineage infection against reinfection with another Omicron sublineage

Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 whow: an in silico analysis

Current and innovative methods for the diagnosis of COVID-19 infection (Review)

European Centre for Disease Prevention and Control. Implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA Event background

Omicron likely to weaken COVID vaccine protection

Omicron (B.1.1.529) variant of SARS-CoV-2: concerns, challenges, and recent updates

Covid-19: time for a paradigm change

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021;2

Omicron incompletely escapes immunity induced by the pfizer vaccine -Africa health research institute

Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv. 2021. Published online

Attenuated fusogenicity and pathogenicity of SARSCoV-2 Omicron variant

Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv: 2021

SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons

Effectiveness of a third dose of mRNA vaccines against COVID-19 associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance

COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Exploring the natural origins of SARS-CoV-2 in the light of recombination

The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic

Omicron, the great escape artist

Zoonotic and reverse zoonotic events of SARS-CoV-2 and their impact on global health

SARS-CoV-2 is associated with changes in brain structure in UK Biobank

Omicron -The new SARS-CoV-2 challenge

The authors would like to acknowledge the contribution of FCT Project Testar, Testar, Testar: "upscalling" do diagnóstico laboratorial